David M.H. Chascsa, M.D.

  1. Gastroenterologist
  2. Internist
  3. Transplant Hepatologist
  1. Liu MC, Lizaola-Mayo B, Jayasekera CR, Mathur AK, Katariya N, Aqel B, Byrne TJ, Chascsa DMH. Downstaging Hepatocellular Carcinoma with Checkpoint Inhibitor Therapy Improves Access to Curative Liver Transplant. J Gastrointest Cancer. 2024 Mar 14 [Epub ahead of print]
    View PubMed
  2. Liu MC, Chumbe JT, Chascsa DMH , Lizaola-Mayo B. Current Management of Hepatic Encephalopathy. Curr Hepatology Rep. 2024; 23:73-80.
  3. Barnhill M, Yaman R, Renszel K, Alzubaidi S, Vargas H, Chascsa D. Not Your Typical Hyperammonemia: Non-hepatic Severe Hyperammonemia in an Adult. ACG Case Rep J. 2023 Dec; 10 (12):e01225 Epub 2023 Dec 13
    View PubMed
  4. Barnhill M, Lizaola-Mayo B, Naidu SG, Shah S, Chascsa DMH. Transjugular intrahepatic portosystemic shunt-induced hemolysis in a non-cirrhotic patient: a case report. J Med Case Rep. 2023 Jun 15; 17 (1):245 Epub 2023 June 15
    View PubMed
  5. Jayasekera CR, Barnhill M, Chascsa DM, Aqel B, Carey EJ, Vargas HE. Fenofibrate Improves Outcomes in Ischemic Cholangiopathy After Liver Transplantation. Gastroenterology 2023 Jun; 164 (7):1321-1323.e2 Epub 2023 Mar 06
    View PubMed
  6. Ashcherkin N, Pisipati S, Athale J, Carey EJ, Chascsa D, Adamski J, Shah S. Solid organ graft-versus-host disease in a recipient of a COVID-19 positive liver graft. J Liver Transpl. 2023 May; 10:100154 Epub 2023 Apr 19
    View PubMed
  7. Aby ES, Moafa G, Latt N, Sultan MT, Cacioppo PA, Kumar S, Chung RT, Bloom PP, Gustafson J, Daidone M, Reinus Z, Debes JD, Sandhu S, Sohal A, Khalid S, Roytman M, Catana AM, Wegermann K, Carr RM, Saiman Y, Kassab I, Chen VL, Rabiee A, Rosenberg C, Nguyen V, Gainey C, Zhou K, Chavin K, Lizaola-Mayo BC, Chascsa DM, Varelas L, Moghe A, Dhanasekaran R. Long-term clinical outcomes of patients with COVID-19 and chronic liver disease: US multicenter COLD study. Hepatol Commun. 2023 Jan 1; 7 (1):e8874 Epub 2023 Jan 03
    View PubMed
  8. Gupta S, Gea-Banacloche J, Me HM, Chascsa DMH, Heilman RL, Budhiraja P, Yaman RN, Vikram HR, Zhang N, Joseph AM, Kodali L. Infections following rejection therapies in kidney and liver transplant recipients. Transpl Infect Dis. 2022 Dec; 24 (6):e13981 Epub 2022 Nov 09
    View PubMed
  9. Katariya NN, Lizaola-Mayo BC, Chascsa DM, Giorgakis E, Aqel BA, Moss AA, Uson Junior PLS, Borad MJ, Mathur AK. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. Cancers (Basel). 2022 Apr 19; 14 (9)
    View PubMed
  10. McCain JD, Chascsa DM. Special Considerations in the Management of HIV and Viral Hepatitis Coinfections in Liver Transplantation. Hepat Med. 2022; 14:27-36. Epub 2022 Apr 29.
    View PubMed
  11. Lizaola-Mayo BC, Dickson RC, Lam-Himlin DM, Chascsa DM. Exogenous copper exposure causing clinical wilson disease in a patient with copper deficiency. BMC Gastroenterol. 2021 Jul 8; 21 (1):278 Epub 2021 July 08
    View PubMed
  12. Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, Perumalswami P, Roytman M, Li M, Vogel AS, Catana AM, Wegermann K, Carr RM, Aloman C, Chen VL, Rabiee A, Sadowski B, Nguyen V, Dunn W, Chavin KD, Zhou K, Lizaola-Mayo B, Moghe A, Debes J, Lee TH, Branch AD, Viveiros K, Chan W, Chascsa DM, Kwo P, Dhanasekaran R. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. Clin Gastroenterol Hepatol. 2021 Jul; 19 (7):1469-1479.e19 Epub 2020 Sept 17
    View PubMed
  13. McCain JD, Chascsa DM, Lindor KD. Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients. Expert Opinion on Orphan Drugs. 2021; 9(2):53-66.
  14. Chascsa DM, Ferre EMN, Hadjiyannis Y, Alao H, Natarajan M, Quinones M, Kleiner DE, Simcox TL, Chitsaz E, Rose SR, Hallgren A, Kampe O, Marko J, Ali RO, Auh S, Koh C, Belkaid Y, Lionakis MS, Heller T. APECED-Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data From a Large, Predominantly American Cohort. Hepatology. 2021 Mar; 73 (3):1088-1104
    View PubMed
  15. Chascsa DMH, Lindor KD. Emerging therapies for PBC. J Gastroenterol. 2020 Mar; 55 (3):261-272 Epub 2020 Jan 22
    View PubMed
  16. Aguilar MT, Chascsa DM. Update on Emerging Treatment Options for Primary Biliary Cholangitis. Hepat Med. 2020; 12:69-77 Epub 2020 May 25
    View PubMed
  17. Tang DM, Chascsa DM, Chou JY, Ho N, Auh S, Wank SA, Koh C, Kumar S. Helicobacter pylori infection is strongly associated with metabolic syndrome, and weakly associated with non-alcoholic fatty liver disease, in a US Hispanic population. GastroHep. 2019 Oct; 1(6).
  18. Chascsa DM, Lindor KD. Cancer risk, screening and surveillance in primary sclerosing cholangitis. Minerva Gastroenterol Dietol. 2019 Sep; 65 (3):214-228 Epub 2019 June 19
    View PubMed
  19. Lizaola-Mayo BC, Vargas HE, Chascsa DM. Hepatitis C-Positive Organs for Liver and Kidney Transplantation - Emerging Data and Current Management Strategies. Curr Hepatol Reports. 2019 May 18; 18(2019):228-32.
  20. DeLeon TT, Salomao MA, Aqel BA, Sonbol MB, Yokoda RT, Ali AH, Moss AA, Mathur AK, Chascsa DM, Rakela J, Bryce AH, Borad MJ. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol. 2018 Dec; 9 (6):1054-1062
    View PubMed
  21. Chascsa DM, Lai JC, Dunn MA, Montano-Loza AJ, Kappus MR, Dasarathy S, Carey EJ. Patient and Caregiver Attitudes and Practices of Exercise in Candidates Listed for Liver Transplantation. Dig Dis Sci. 2018 Dec; 63 (12):3290-3296 Epub 2018 Sept 03
    View PubMed
  22. Chascsa DM, Mousa OY, Pungpapong S, Zhang N, Chervenak A, Nidamanuri S, Rodriguez E, Franco D, Ryland K, Keaveny AP, Huskey JL, Smith M, Reddy KS, Taner CB, Vargas HE, Aqel BA. Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter study. Am J Transplant. 2018 Oct; 18 (10):2559-2565 Epub 2018 June 08
    View PubMed
  23. Chascsa DM, Rakela J. Knowns and Unknowns: the Safety and Efficacy of Cancer Immunotherapy in Chronic Liver Disease. Curr Hepatology Rep. 2018; 17(3):153-155.
  24. Chascsa DM, Lindor KD. Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: Is It Really the Same Disease? Clin Liver Dis. 2018 Aug; 22 (3):589-601
    View PubMed
  25. Chascsa DM, Vargas HE. The gastroenterologist's guide to management of the post-liver transplant patient. Am J Gastroenterol. 2018 Jun; 113 (6):819-828 Epub 2018 May 11
    View PubMed
  26. Chascsa D, Carey EJ, Lindor KD. Old and new treatments for primary biliary cholangitis. Liver Int. 2017 Apr; 37 (4):490-499
    View PubMed
  27. Ferre EM, Rose SR, Rosenzweig SD, Burbelo PD, Romito KR, Niemela JE, Rosen LB, Break TJ, Gu W, Hunsberger S, Browne SK, Hsu AP, Rampertaap S, Swamydas M, Collar AL, Kong HH, Lee CR, Chascsa D, Simcox T, Pham A, Bondici A, Natarajan M, Monsale J, Kleiner DE, Quezado M, Alevizos I, Moutsopoulos NM, Yockey L, Frein C, Soldatos A, Calvo KR, Adjemian J, Similuk MN, Lang DM, Stone KD, Uzel G, Kopp JB, Bishop RJ, Holland SM, Olivier KN, Fleisher TA, Heller T, Winer KK, Lionakis MS. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight. 2016 Aug 18; 1: (13).
    View PubMed
  28. Mandell MS, Seres T, Lindenfeld J, Biggins SW, Chascsa D, Ahlgren B, Wachs M, Bambha KM. Risk factors associated with acute heart failure during liver transplant surgery: a case control study. Transplantation. 2015 Apr; 99: (4)873-8.
    View PubMed